Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development

Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin